secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEOGENOMICS INC (NEO)
CIK:        0001077183
Form:       8-K
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001077183-22-000132
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeoGenomics Q2 revenue $125M (+3%), net loss $35M; appoints Chris Smith CEO
---------------------------------------------------------------------------

- Revenue $125M (+3% YoY); Clinical $106M (+4%), Pharma $19M (-4%). Net loss $35M vs $76M income (incl $97M Inivata gain).
- Adjusted EBITDA negative $16M vs positive $5M in Q2 2021; adjusted net loss $20M vs $1M.
- Chris Smith appointed CEO effective Aug 15; Vishal Sikri named President, Pharma Services in May.
- Cash and securities $466M; company launched enterprise-wide performance improvement plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1077183/000107718322000132/0001077183-22-000132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1077183/000107718322000132/neo-20220809.htm
  HTML page:      https://secwatch.observer/filing/0001077183-22-000132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer